Merck’s ERVEBO Zaire ebolavirus vaccine was approved by the U.S. Food and Drug Administration ( FDA ) on August 3, 2023, for people 12 months of age and older. The vaccine was originally approved for people who were at least 18 years old.
Merck receives FDA approval for the Ebola vaccine at https :// t.co / Tnm4dVJ3Wz pic. twitter.com / Lfubls9VSf
20 December 2019 — Reuters(@ Reuters )
Merck declared:
The U.S. Food and Drug Administration ( FDA ) has approved an expanded indication for ERVEBO, which is now intended for the prevention of disease brought on by the Zaire ebolavirus in people 12 months of age and older, according to Merck( NYSE: MRK ), also known as MSD outside of the United States and Canada. The vaccine was recently authorized for use in people who were at least 18 years old. The duration of protection provided by ERVEBO is unknown, and it does not provide protection against different species of Ebolavirus or Marburgvirus. It is unknown how well the vaccine works when combined with antiviral drugs, immune globulin( IG ), and / or blood or plasma transfusions. ERVEBO includes a contraindication to any component of the vaccine, including rice protein, for people who have previously experienced severe allergic reactions( e.g., anaphylaxis ).
The” Ebola virus disease is deadly and may be fatal in both children and adults.” According to Dr. Eliav Barr, senior vice president, head of international scientific development, and chief clinical officer at Merck Research Laboratories,” We’re proud of the approval of ERVEBO for the prevention of disease caused by Zaire ebolavirus in children as young as 12 months old, which is another milestone in our continued commitment to help address the global health threat caused.
Separately, on July 20, 2023, the European Medicines Agency’s Committee for Medicinal Products for Human Use ( CHMP ) recommended expanding the approval of the ERVEBO ®] Ebola Zaire Vaccine, ( rVSVG – ZEBOV – GP ) live ], for active immunization of people one year of age or older to protect against the virus disease( EVD ) brought on by the Ziaire virus. For people 18 years of age and older, ERVEBO is currently permitted for use in the European Union( EU ). The European Commission will now consider the CHMP opinion for amending the marketing authorization, and a decision is anticipated in the second quarter of 2023.
a commercial
Given the Ebola rumors at Burning Man, the timing will raise questions.
Coincidence? Pic of the Ebola BurningMan2023 XGQjEPsI3A twitter.com
— September 3, 2023, Robin Monotti (@ robinmonotti )
Although there have been rumors that quarantines at the” festival” were brought on by Ebola, these claims are currently unfounded.
Check out a complete fact- Ok.
FACT – CHECK: Why Is Quarantine At” Burning Man” Due To Ebola?
However, we should continue to be on the lookout for any dubious Big Pharma activity.
One of the producers of mRNA COVID-19 shots, Moderna, wants to use it in an Ebola shot.
according to Reuters in 2022:
MRNA Moderna Inc. Bloomberg News reported on Wednesday, citing sources with knowledge of the situation, that O ) is close to a deal with the U.S. government to develop vaccines against various biological threats, including Ebola.
According to the report, Moderna’s mRNA technology would be used in the potential agreement with the U.S. Department of Defense ( DoD) to create a vaccine that would specifically target the Ebola strain that caused the outbreak in Uganda.
Ebola has already claimed 30 lives in Uganda since the country’s September outbreak, and 109 cases have been confirmed.
According to the report, Moderna’s shot would even target the Marburg virus and the more prevalent Zaire strain of Ebola.
The pharmaceutical company said it” continued to explore possible Ebola vaccines” and has a preliminary program for the disease but declined to comment on any potential contracts.
The$ 25 million contract to” design, manufacture, and test mRNA vaccines for Ebola” was ultimately completed by the U.S. government.
https: // t.$ MRNA US inks 25 million deal to fight ebola with cutting-edge technology. co / 8diFxcpypH
— Minos, January 11, 2023 (@ enconomics )
UTMB Health published:
Over the course of three years, researchers at the University of Texas Medical Branch in Galveston and Moderna received$ 13.5 million to develop, produce, and test Ebola mRNA vaccines. An additional$ 11.1 million could be given to UTMB to research different ways to administer the vaccines. The contract is a component of the US’s larger effort to safeguard defense personnel with technology that made it possible for COVID-19 vaccines to be developed quickly before the pandemic. This story was also covered by numerous provincial and international news outlets.
The U.S. Food and Drug Administration approved Merck’s ERVEBO Zaire ebolavirus vaccination for individuals aged 12 months and older on August 3, 2023. The vaccine had previously been approved for those aged 18 years and older.
Merck receives FDA approval for Ebola vaccine https://t.co/Tnm4dVJ3Wz pic.twitter.com/Lfubls9VSf
— Reuters December 20, 2019
Merck announces:
Merck (NYSE MRK), also known as MSD in the United States and Canada announced today that the U.S. Food and Drug Administration has approved a new indication for ERVEBO. It is now indicated to prevent disease caused by Zaire ebolavirus among individuals aged 12 months and older. Previously, the vaccine was approved for individuals 18 years and older. ERVEBO cannot protect against other species Ebolaviruses or Marburgviruses, and the duration of protection conferred is unknown. The effectiveness of the vaccination when administered in conjunction with antiviral medications, immune globulins (IG), blood or plasma transfusions, and/or immune globulins is unknown. ERVEBO has a contraindication if you have a history of severe allergic reactions (e.g. anaphylaxis), to any component of this vaccine, including the rice protein.
Ebola virus is contagious, and can be deadly to both children and adults. We are proud that ERVEBO has been approved for the prevention of Zaire ebolavirus disease in children as young 12 months old. This is another milestone in Merck Research Laboratories’ commitment to address the global health threats caused by Zaire ebolavirus.
Separately, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use recommended, on July 20,2023, the expanded approval of ERVEBO (r) [Ebola Zaire Vaccine (rVSVDGZEBOV-GP) Live], for the active immunization against Ebola Virus Disease caused by Zaire ebolavirus in individuals aged 1 year or older. ERVEBO has been approved for use in the European Union for those 18 years and older. The European Commission will now consider the CHMP opinion for amending the marketing authorisation. A final decision is expected to be made in the third quarter 2023.
Advertisement
The timing of the Ebola rumors at Burning Man will raise suspicions.
Coincidence? #Ebola #BurningMan2023 #burningmanebola pic.twitter.com/XGQjEPsI3A
— Robin Monotti (@robinmonotti) September 3, 2023
The claims that Ebola quarantines were caused by the “festival” are not valid.
Click HERE to read the full fact-check.
FACT-CHECK: Quarantine At “Burning Man” Because Of Ebola?
We should continue to be on the lookout for any suspicious Big Pharma activity.
Moderna, a manufacturer of mRNA COVID-19 shots, wants to use mRNA technology in an Ebola vaccine.
Per Reuters, 2022
Bloomberg News reported Wednesday that Moderna Inc. (MRNA.O), citing sources familiar with the matter, is close to a deal with U.S. Government to develop vaccines for a range biological threats, including Ebola.
The report stated that Moderna’s mRNA-based technology would be used to develop a vaccine against the Ebola strain responsible in Uganda for the outbreak of the disease.
Uganda declared an Ebola outbreak on September 1st. The disease has already claimed 30 lives and 109 confirmed cases.
The report also added that Moderna’s shot would target the more common Zaire Ebola strain and the related Marburg viral.
The drugmaker declined comment on any potential contract but said that it “continued exploring potential Ebola vaccinations” and currently has a program for Ebola in preclinical testing.
The U.S. Government finally finalized a deal worth $25 million to “design, produce and test mRNA vaccinations for Ebola.”
$MRNA US inks 25-million deal to fight ebola with moderna technologyhttps://t.co/8diFxcpypH
Minos (@enconomics), January 11, 2023
UTMB Health wrote the following:
Scientists at the University of Texas Medical Branch in Galveston received $13.5 million over a three-year period to design, manufacture, and test mRNA Ebola vaccines. UTMB may receive an additional $11.1m to study alternative methods of administering vaccines. The contract is part a larger push by the US for military personnel to be protected using technology that allowed the quick development COVID-19 vaccines during the early pandemic. This story was also covered by many international and regional media outlets.
